Novo Nordisk licenses hypoglycemia drug from Zealand Pharma

Novo Nordisk will pay an upfront sum of DKK 25m (USD 3.3m) and up to DKK 290m (USD 38.7m) including longer-term milestone payments for dasiglucacon. (Updated)

Photo: Novo Nordisk / PR

Zealand Pharma and Novo Nordisk have entered a licensing and development agreement over dasiglucacon, which is approved in the US and marketed as Zegalogue.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs